Traditional Chinese Medicine Regulates Signaling Pathways Related to Precancerous Lesions of Gastric Cancer： A Review
10.13422/j.cnki.syfjx.20242297
- VernacularTitle:中医药干预胃癌前病变相关信号通路的研究进展
- Author:
Maofu ZHANG
1
;
Xinyu LI
1
;
Yanyun SHEN
1
;
Yeyuan LIU
1
;
Jialin ZHONG
1
;
Lulu CHEN
1
;
Haihong ZHAO
1
;
Zhongyang SONG
2
;
Zhiming ZHANG
3
Author Information
1. Gansu University of Chinese Medicine，Lanzhou 730000，China
2. Affiliated Hospital of Gansu University of Chinese Medicine，Lanzhou 730020，China
3. Gansu Provincial Hospital of Traditional Chinese Medicine，Lanzhou 730050，China
- Publication Type:Journal Article
- Keywords:
precancerous lesions of gastric cancer;
signaling pathway;
traditional Chinese medicine;
research progress
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(4):297-306
- CountryChina
- Language:Chinese
-
Abstract:
Precancerous lesions of gastric cancer （PLGC） are a group of pathological changes caused by abnormalities in the structure， morphology， and differentiation of gastric mucosal epithelial cells. Since the early symptoms are hidden and non-specific， PLGC is not easy to be diagnosed and it has often developed into intermediate or advanced gastric cancer once being diagnosed and missed the best time for treatment. Accordingly， the incidence of this disease is increasing year by year， which lifts a heavy burden on the patients. The pathogenesis of PLGC is complex， involving inflammatory microenvironment， bile reflux， glycolysis， autophagy， and apoptosis. Currently， PLGC is mainly treated with anti-inflammatory and endoscopic therapies， which are difficult to curb the development of PLGC. Therefore， seeking a safe and effective therapy is an important topic of modern research. Traditional Chinese medicine （TCM）， characterized by treatment based on syndrome differentiation and a holistic view， exerts effects via multiple pathways， mechanisms， and targets. Recent studies have confirmed that TCM can regulate the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin （PI3K/Akt/mTOR）， Wnt/β-catenin， Sonic Hedgehog， nuclear factor-κB （NF-κB）， Janus kinase/signal transducer and activator of transcription （JAK/STAT）， hypoxia-inducible factor-1α （HIF-1α）， neurogenic locus notch homolog protein （Notch）， nuclear factor E2-related factor 2 （Nrf2） and other signaling pathways. By targeting these pathways， TCM can inhibit aerobic glycolysis， reduce oxidative stress， repair the inflammatory microenvironment， regulate cellular autophagy， and promote vascular normalization， thereby delaying or reversing PLGC. However， few researchers have systematically summarized the TCM regulation of PLGC-associated pathways. By reviewing the relevant articles at home and abroad， this paper summarized the roles of the above signaling pathways in the development of PLGC and the research progress in the regulation of signaling pathways by TCM in the treatment of PLGC， with a view to providing a new theoretical basis for the clinical research on PLGC and the drug development for this disease.
